Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Xeligekimab - Genrix (Shanghai) Biopharmaceuticals

Next Previous
X
Search
Drug Profile

Xeligekimab - Genrix (Shanghai) Biopharmaceuticals

Alternative Names: GR-1501; Jinlixi

Latest Information Update: 11 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genrix (Shanghai) Biopharmaceuticals
  • Class Antipsoriatics; Antirheumatics; Monoclonal antibodies; Recombinant proteins; Skin disorder therapies
  • Mechanism of Action IL17A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Plaque psoriasis
  • Preregistration Axial spondyloarthritis
  • Phase II Lupus nephritis
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 11 Sep 2024 Discontinued - Preclinical for Rheumatoid arthritis in China (Parenteral)
  • 11 Sep 2024 Launched for Plaque psoriasis in China (SC) - First global launch, before September 2024 (Generix (Shanghai) Biopharmaceutical website, September 2024)
  • 11 Sep 2024 Phase-II clinical trials in Lupus nephritis (Parenteral), before September 2024 (Genrix (Shanghai) Biopharmaceuticals pipeline, September 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top